Kinnate Biopharma sells exarafenib to Pierre Fabre Laboratories

Kinnate Biopharma and Pierre Fabre Medicament announced their agreement to the sale of the company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties. The sale of global rights is in furtherance of the company’s previously announced exploration of strategic alternatives. Under the terms of the APA, Pierre Fabre Laboratories has purchased exarafenib and other pan-RAF assets and will assume 100% of the ongoing program and costs associated with these assets. In consideration, Kinnate will receive a total consideration of up to $31M, consisting of $500,000 at closing, and a $30.5M payment, contingent upon the earlier of the dosing of the first patient in the first pivotal trial for exarafenib or any other acquired asset, or the application for an accelerated approval pursuant to the FDA’s Accelerated Approval Program for exarafenib or any other acquired asset, or the submission of a marketing application for regulatory approval for exarafenib or any other acquired asset. In addition, Pierre Fabre Laboratories will assume up to $5M of trade payables for the transferred assets. The transaction is not subject to closing conditions and closed upon signing.